An analysis of cash collection systems related to the European drug market


Money laundering is practised exclusively by criminal organisations that have attained a proven level of professionalism. It occurs at a certain point in the criminal cycle because it enables an illicit enterprise to legitimise the origin of their funds and benefit from their gains while remaining unpunished. Nonetheless, most professional traffickers think in a sequential manner, that is, first they are interested in how to set up their activity (purchase, logistics, distribution) and only much later in how they are going to hide the origin of the profits they make.

However, the money-laundering phase is crucial for those involved in the criminal world. Moreover, public authorities have been working to combat money laundering for more than thirty years, with, of course, varying degrees of success, depending on the relevant legal provisions, their application and preventive effects.

In the context of the European drug market, this paper provides an exploratory analysis of a method of laundering drug money that law enforcement agencies (LEAs) identify through the use of ‘cash collectors’. We first highlight the main actors of cash collecting linked to drug trafficking, then we discuss its organisation, especially the interpenetration of networks, and, finally, we highlight some salient elements of public responses to the problem in a number of European countries.

Download as PDF

An analysis of cash collection systems related to the European drug market

PDF files are made available as a convenience. In cases where the EMCDDA is not the originator of the document, please be aware that any PDFs available on this page may not be authoritative or there may be more recent versions available. While we make every effort to ensure that these files are definitive, before using or citing them, we recommend that you consult the publisher's website or contact the author(s) to check for more recent versions.

Additional information

This Background paper was commissioned by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (contract CT.21.SAS0056.1.0). We are grateful for the valuable contribution of the author. The paper has been cited within various reports and is also being made available online for those who would like further information on the topic. However, the views, interpretations and conclusions set out in this publication are those of the authors and are not necessarily those of the EMCDDA or its partners, any EU Member State or any agency or institution of the European Union.